Jupiter Asset Management Ltd. purchased a new stake in shares of Quanterix Co. (NASDAQ:QTRX – Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 20,549 shares of the company’s stock, valued at approximately $558,000.
A number of other hedge funds also recently added to or reduced their stakes in the company. Advisor Group Holdings Inc. lifted its stake in Quanterix by 184.6% during the 1st quarter. Advisor Group Holdings Inc. now owns 885 shares of the company’s stock valued at $404,000 after acquiring an additional 574 shares during the period. US Bancorp DE lifted its position in Quanterix by 35.6% during the second quarter. US Bancorp DE now owns 1,709 shares of the company’s stock valued at $39,000 after purchasing an additional 449 shares during the period. PNC Financial Services Group Inc. lifted its position in Quanterix by 73.9% during the first quarter. PNC Financial Services Group Inc. now owns 1,845 shares of the company’s stock valued at $53,000 after purchasing an additional 784 shares during the period. Lazard Asset Management LLC purchased a new position in shares of Quanterix in the 2nd quarter worth $47,000. Finally, Robeco Institutional Asset Management B.V. purchased a new stake in Quanterix during the third quarter valued at $67,000. 86.64% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Separately, Scotiabank started coverage on Quanterix in a research note on Thursday, February 1st. They set a “sector outperform” rating and a $30.00 price target for the company. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Quanterix presently has an average rating of “Buy” and an average target price of $31.60.
Quanterix Stock Performance
NASDAQ:QTRX opened at $24.28 on Monday. Quanterix Co. has a one year low of $10.02 and a one year high of $28.78. The business has a fifty day moving average price of $24.70 and a 200-day moving average price of $24.23.
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. It offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids.
- Five stocks we like better than Quanterix
- How to Invest in Renewable Energy
- Uber quadruples EPS estimates, but is growth decelerating?
- How to Calculate Stock Profit
- 3 stocks set to benefit from record Valentine’s Day spending
- What Are Utility Stocks? An Overview of the Utilities Sector
- Tradeweb is a disruptive pure play on financial market liquidity
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.